SG11201811709WA - Compounds, compositions, and methods for the treatment of disease - Google Patents
Compounds, compositions, and methods for the treatment of diseaseInfo
- Publication number
- SG11201811709WA SG11201811709WA SG11201811709WA SG11201811709WA SG11201811709WA SG 11201811709W A SG11201811709W A SG 11201811709WA SG 11201811709W A SG11201811709W A SG 11201811709WA SG 11201811709W A SG11201811709W A SG 11201811709WA SG 11201811709W A SG11201811709W A SG 11201811709WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- shrewsbury
- july
- compositions
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 241000286209 Phasianidae Species 0.000 abstract 2
- 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 abstract 1
- 101710127675 Antiviral innate immune response receptor RIG-I Proteins 0.000 abstract 1
- 241000218645 Cedrus Species 0.000 abstract 1
- 101001082073 Homo sapiens Interferon-induced helicase C domain-containing protein 1 Proteins 0.000 abstract 1
- 102100027353 Interferon-induced helicase C domain-containing protein 1 Human genes 0.000 abstract 1
- 241000218657 Picea Species 0.000 abstract 1
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- ZTQSADJAYQOCDD-UHFFFAOYSA-N ginsenoside-Rd2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OCC(O)C(O)C1O ZTQSADJAYQOCDD-UHFFFAOYSA-N 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102000007863 pattern recognition receptors Human genes 0.000 abstract 1
- 108010089193 pattern recognition receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662359039P | 2016-07-06 | 2016-07-06 | |
| US201662363118P | 2016-07-15 | 2016-07-15 | |
| US201662403530P | 2016-10-03 | 2016-10-03 | |
| US201662411424P | 2016-10-21 | 2016-10-21 | |
| US201762444141P | 2017-01-09 | 2017-01-09 | |
| US201762462679P | 2017-02-23 | 2017-02-23 | |
| US201762470746P | 2017-03-13 | 2017-03-13 | |
| US201762508846P | 2017-05-19 | 2017-05-19 | |
| PCT/US2017/040882 WO2018009648A1 (en) | 2016-07-06 | 2017-07-06 | Compounds, compositions, and methods for the treatment of disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201811709WA true SG11201811709WA (en) | 2019-01-30 |
Family
ID=60913147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201811709WA SG11201811709WA (en) | 2016-07-06 | 2017-07-06 | Compounds, compositions, and methods for the treatment of disease |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11033569B2 (he) |
| EP (1) | EP3481402A4 (he) |
| JP (3) | JP7100227B2 (he) |
| KR (1) | KR102569881B1 (he) |
| CN (1) | CN109843302B (he) |
| AU (1) | AU2017293781B2 (he) |
| CA (1) | CA3029644A1 (he) |
| IL (1) | IL264049B2 (he) |
| MX (2) | MX2019000216A (he) |
| SG (1) | SG11201811709WA (he) |
| TW (1) | TWI689514B (he) |
| WO (1) | WO2018009648A1 (he) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114230625A (zh) | 2016-03-18 | 2022-03-25 | 免疫传感器公司 | 环二核苷酸化合物及使用方法 |
| IL264049B2 (he) * | 2016-07-06 | 2023-11-01 | Sperovie Biosciences Inc | תרכובות, תכשירים ושיטות לטיפול במחלה |
| JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
| CN110650976B (zh) | 2017-04-13 | 2024-04-19 | 赛罗帕私人有限公司 | 抗SIRPα抗体 |
| AR113224A1 (es) | 2017-04-28 | 2020-02-19 | Novartis Ag | Conjugados de anticuerpo que comprenden un agonista de sting |
| CA3082351A1 (en) | 2017-11-10 | 2019-05-16 | Takeda Pharmaceutical Company Limited | Sting modulator compounds, and methods of making and using |
| AU2018392213B2 (en) | 2017-12-20 | 2021-03-04 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
| JP7098748B2 (ja) | 2017-12-20 | 2022-07-11 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する２’３’環状ジヌクレオチド |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| WO2020014127A1 (en) * | 2018-07-10 | 2020-01-16 | Sperovie Biosciences, Inc. | Compounds, compositions, and methods for the treatment of disease |
| TW202030199A (zh) * | 2018-07-17 | 2020-08-16 | 美商健生生物科技公司 | 作為ｓｔｉｎｇ促效劑之環狀二核苷酸 |
| KR20230122685A (ko) | 2018-09-06 | 2023-08-22 | 다이이찌 산쿄 가부시키가이샤 | 신규 고리형 디뉴클레오티드 유도체 및 그 항체 약물콘쥬게이트 |
| CN110938104A (zh) | 2018-09-21 | 2020-03-31 | 上海迪诺医药科技有限公司 | 环状二核苷酸类似物、其药物组合物及应用 |
| AU2019371206A1 (en) | 2018-10-29 | 2021-05-27 | Venenum Biodesign, LLC | Novel sting agonists |
| US11110106B2 (en) | 2018-10-29 | 2021-09-07 | Venenum Biodesign, LLC | Sting agonists for treating bladder cancer and solid tumors |
| WO2020092617A1 (en) | 2018-10-31 | 2020-05-07 | Novartis Ag | Dc-sign antibody conjugates comprising sting agonists |
| CN111423483A (zh) * | 2019-01-10 | 2020-07-17 | 南开大学 | 环二核苷酸前药分子及其制备方法和应用 |
| EP3934757B1 (en) | 2019-03-07 | 2023-02-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| CN113574063A (zh) | 2019-03-07 | 2021-10-29 | 捷克共和国有机化学与生物化学研究所 | 3’3’-环二核苷酸及其前药 |
| CA3137119A1 (en) | 2019-05-09 | 2020-11-12 | Aligos Therapeutics, Inc. | Modified cyclic dinucleoside compounds as sting modulators |
| CA3145889A1 (en) | 2019-07-05 | 2021-01-14 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| WO2021177438A1 (ja) | 2020-03-06 | 2021-09-10 | 第一三共株式会社 | 新規環状ジヌクレオチド誘導体を含む抗体薬物コンジュゲート |
| KR20220167275A (ko) | 2020-04-10 | 2022-12-20 | 오노 야꾸힝 고교 가부시키가이샤 | 암 치료 방법 |
| CN111909223A (zh) * | 2020-07-17 | 2020-11-10 | 清华大学 | 环二核苷酸共价修饰物及其制备方法和应用 |
| CN116056765A (zh) | 2020-08-07 | 2023-05-02 | 坦伯公司 | 反式环辛烯生物正交剂及在癌症和免疫疗法中的用途 |
| TW202227479A (zh) | 2020-09-02 | 2022-07-16 | 日商第一三共股份有限公司 | 新穎內－β－Ｎ－乙醯葡萄糖胺苷酶 |
| JP7397996B2 (ja) | 2020-11-09 | 2023-12-13 | 武田薬品工業株式会社 | 抗体薬物コンジュゲート |
| WO2024076728A1 (en) * | 2022-10-06 | 2024-04-11 | Dana-Farber Cancer Institute, Inc. | Cyclic nucleotides and uses thereof |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2257704B (en) * | 1991-07-18 | 1995-03-01 | Erba Carlo Spa | Cyclic oligonucleotides phosphorothioates |
| EP2371834B1 (en) * | 2003-06-11 | 2016-02-17 | Idera Pharmaceuticals, Inc. | Stabilized immunomodulatory oligonucleotides |
| US7592326B2 (en) * | 2004-03-15 | 2009-09-22 | Karaolis David K R | Method for stimulating the immune, inflammatory or neuroprotective response |
| US7569555B2 (en) * | 2004-03-15 | 2009-08-04 | Karaolis David K R | Method for stimulating the immune, inflammatory or neuroprotective response |
| EP2448954A1 (en) * | 2009-07-01 | 2012-05-09 | Rutgers, The State University of New Jersey | Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof |
| CN102199183B (zh) * | 2010-03-26 | 2013-12-18 | 北京大学 | 环二鸟苷酸及其类似物和制备方法 |
| NZ702392A (en) | 2012-06-08 | 2017-03-31 | Aduro Biotech | Compositions and methods for cancer immunotherapy |
| EA201590396A1 (ru) * | 2012-12-13 | 2015-12-30 | Адуро Биотек, Инк. | Композиция, содержащая циклические пуриновые динуклеотиды с определенной стереохимией, и способ ее получения и применения |
| EP2934598B1 (en) * | 2012-12-19 | 2018-04-18 | Board Of Regents, The University Of Texas System | Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway |
| JP6243443B2 (ja) * | 2012-12-20 | 2017-12-06 | ヒルズ・ペット・ニュートリシャン・インコーポレーテッド | 全身健康状態の尺度としてのパターン認識受容体の発現 |
| JP6153116B2 (ja) * | 2013-01-09 | 2017-06-28 | 国立大学法人東北大学 | トリアゾール連結型環状ジヌクレオチド類縁体 |
| EP2762154A3 (en) | 2013-02-05 | 2015-01-21 | Nitto Denko Corporation | Vaccine composition for transdermal administration |
| JP2016518140A (ja) | 2013-05-03 | 2016-06-23 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｉ型インターフェロンの環状ジヌクレオチド誘導法 |
| MY175308A (en) * | 2013-05-18 | 2020-06-18 | Aduro Biotech Inc | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
| CN103864910B (zh) * | 2014-03-03 | 2016-01-20 | 中国科学院南海海洋研究所 | 一种新型特异结合lps的贝类模式识别受体lrrp |
| KR20200029627A (ko) | 2014-03-12 | 2020-03-18 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소 |
| ES2692226T3 (es) | 2014-06-04 | 2018-11-30 | Glaxosmithkline Intellectual Property Development Limited | Dinucleótidos cíclicos como moduladores de STING |
| US20170340658A1 (en) | 2014-12-16 | 2017-11-30 | Invivogen | Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment |
| EP3546473A1 (en) * | 2014-12-16 | 2019-10-02 | Kayla Therapeutics | Cyclic [(2',5')p(3',5')p]-dinucleotides for cytokine induction |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| PE20171448A1 (es) * | 2015-03-10 | 2017-10-02 | Aduro Biotech Inc | Composiciones y metodos para activar la senalizacion dependiente del estimulador del gen de interferon |
| MA42608A (fr) | 2015-08-13 | 2018-06-20 | Merck Sharp & Dohme | Composés de di-nucléotide cyclique en tant qu'agonistes sting (stimulateur de gène interféron) |
| AU2016343993A1 (en) | 2015-10-28 | 2018-05-10 | Aduro Biotech, Inc. | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
| NZ738202A (en) * | 2015-12-03 | 2019-07-26 | Glaxosmithkline Ip Dev Ltd | Cyclic purine dinucleotides as modulators of sting |
| CN106540260A (zh) | 2015-12-09 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | 干扰素基因刺激蛋白（sting）激动剂在抗阿尔兹海默症中的应用 |
| US20180369268A1 (en) * | 2015-12-16 | 2018-12-27 | Aduro Biotech, Inc. | Methods for identifying inhibitors of "stimulator of interferon gene"- dependent interferon production |
| US10723756B2 (en) | 2016-01-11 | 2020-07-28 | Innate Tumor Immunity Inc. | Cyclic dinucleotides for treating conditions associated with STING activity such as cancer |
| EP3402801A1 (en) | 2016-01-11 | 2018-11-21 | Innate Tumor Immunity, Inc. | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer |
| KR20180114946A (ko) | 2016-03-02 | 2018-10-19 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 면역요법을 위한 sting 활성화 나노백신 |
| EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
| IL264049B2 (he) * | 2016-07-06 | 2023-11-01 | Sperovie Biosciences Inc | תרכובות, תכשירים ושיטות לטיפול במחלה |
| WO2018045204A1 (en) | 2016-08-31 | 2018-03-08 | Ifm Therapeutics, Inc | Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity |
| UA125223C2 (uk) | 2016-10-04 | 2022-02-02 | Мерк Шарп І Доум Корп. | СПОЛУКИ БЕНЗО[b]ТІОФЕНУ ЯК АГОНІСТИ STING |
| JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
| WO2018118665A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Cyclic dinucleotide sting agonists for cancer treatment |
| RU2019122602A (ru) | 2016-12-20 | 2021-01-22 | Мерк Шарп И Доум Корп. | Комбинации антагонистов pd-1 и циклических динуклеотидных агонистов sting для лечения рака |
| JP2020508310A (ja) | 2017-02-21 | 2020-03-19 | ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | インターフェロン遺伝子刺激因子依存性シグナル伝達のアゴニストとしての環状ジヌクレオチド |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| WO2018208667A1 (en) | 2017-05-12 | 2018-11-15 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as sting agonists |
| CA3067257A1 (en) | 2017-06-22 | 2018-12-27 | Curadev Pharma Limited | Small molecule modulators of human sting |
| WO2018234807A1 (en) | 2017-06-22 | 2018-12-27 | Curadev Pharma Limited | HETEROCYCLIC MODULATORS WITH SMALL MOLECULES OF HUMAN STING |
| WO2018234805A1 (en) | 2017-06-22 | 2018-12-27 | Curadev Pharma Limited | SMALL MOLECULAR MODULATORS OF HUMAN STING |
| WO2019051489A1 (en) * | 2017-09-11 | 2019-03-14 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE |
-
2017
- 2017-07-06 IL IL264049A patent/IL264049B2/he unknown
- 2017-07-06 MX MX2019000216A patent/MX2019000216A/es unknown
- 2017-07-06 AU AU2017293781A patent/AU2017293781B2/en active Active
- 2017-07-06 JP JP2019520928A patent/JP7100227B2/ja active Active
- 2017-07-06 TW TW106122757A patent/TWI689514B/zh active
- 2017-07-06 CN CN201780054031.7A patent/CN109843302B/zh active Active
- 2017-07-06 SG SG11201811709WA patent/SG11201811709WA/en unknown
- 2017-07-06 EP EP17824876.1A patent/EP3481402A4/en active Pending
- 2017-07-06 US US16/315,472 patent/US11033569B2/en active Active
- 2017-07-06 KR KR1020197003440A patent/KR102569881B1/ko active IP Right Grant
- 2017-07-06 WO PCT/US2017/040882 patent/WO2018009648A1/en unknown
- 2017-07-06 CA CA3029644A patent/CA3029644A1/en active Pending
-
2019
- 2019-01-07 MX MX2022006260A patent/MX2022006260A/es unknown
-
2021
- 2021-06-04 US US17/339,484 patent/US11744845B2/en active Active
-
2022
- 2022-05-12 JP JP2022078657A patent/JP2022106989A/ja active Pending
-
2023
- 2023-09-26 JP JP2023162456A patent/JP2023182645A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3481402A1 (en) | 2019-05-15 |
| US11033569B2 (en) | 2021-06-15 |
| CA3029644A1 (en) | 2018-01-11 |
| IL264049A (he) | 2019-01-31 |
| TW201805295A (zh) | 2018-02-16 |
| JP7100227B2 (ja) | 2022-07-13 |
| JP2019532084A (ja) | 2019-11-07 |
| KR20190032408A (ko) | 2019-03-27 |
| JP2023182645A (ja) | 2023-12-26 |
| CN109843302B (zh) | 2022-11-29 |
| CN109843302A (zh) | 2019-06-04 |
| AU2017293781B2 (en) | 2022-12-22 |
| US20190262372A1 (en) | 2019-08-29 |
| IL264049B2 (he) | 2023-11-01 |
| MX2019000216A (es) | 2019-11-12 |
| TWI689514B (zh) | 2020-04-01 |
| EP3481402A4 (en) | 2020-01-22 |
| US11744845B2 (en) | 2023-09-05 |
| IL264049B1 (he) | 2023-07-01 |
| JP2022106989A (ja) | 2022-07-20 |
| WO2018009648A1 (en) | 2018-01-11 |
| AU2017293781A1 (en) | 2019-02-07 |
| KR102569881B1 (ko) | 2023-08-22 |
| MX2022006260A (es) | 2022-06-29 |
| US20220054523A1 (en) | 2022-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811709WA (en) | Compounds, compositions, and methods for the treatment of disease | |
| SG11201900154VA (en) | Compounds, compositions, and methods for the treatment of disease | |
| SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
| SG11201901834WA (en) | Micrornas as biomarkers for endometriosis | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201903697WA (en) | Liver organoid compositions and methods of making and using same | |
| SG11201807252QA (en) | Anti-lag-3 antibodies | |
| SG11201805888SA (en) | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer | |
| SG11201804162WA (en) | Compositions comprising bacterial strains | |
| SG11201806322QA (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
| SG11201407873RA (en) | Endoscopic sympathectomy systems and methods | |
| SG11201900501RA (en) | Cannabis composition | |
| SG11201909009TA (en) | Catheter securement device with window | |
| SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
| SG11201909561RA (en) | Octree-based convolutional neural network | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201900665VA (en) | Cannabis composition | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201809474TA (en) | Compositions and methods for bioengineered tissues | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201903202VA (en) | Osmotic membrane | |
| SG11201805755SA (en) | Methods of administering hepcidin | |
| SG11201909107YA (en) | Stenosis treatment | |
| SG11201810192TA (en) | Antibacterial compositions | |
| SG11201906807VA (en) | Compositions and methods for promoting hair growth with mpc1 inhibitors |